A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Hummingbird Bioscience
Novartis
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Fate Therapeutics
Alterome Therapeutics, Inc.
Verastem, Inc.
Novartis
Revolution Medicines, Inc.
Pfizer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
AstraZeneca
Incyte Corporation
Eli Lilly and Company
Pfizer
Pfizer
Tizona Therapeutics, Inc
Genentech, Inc.
SWOG Cancer Research Network
Revolution Medicines, Inc.
Jacobio Pharmaceuticals Co., Ltd.
Memorial Sloan Kettering Cancer Center
PAQ Therapeutics, Inc.
Eli Lilly and Company
Bristol-Myers Squibb
Bristol-Myers Squibb
Servier
Genentech, Inc.
Eli Lilly and Company
Genfleet Therapeutics (Shanghai) Inc.
Bristol-Myers Squibb
InventisBio Co., Ltd
Innovent Biologics (Suzhou) Co. Ltd.
Pfizer
GlaxoSmithKline
University of Turin, Italy
The Netherlands Cancer Institute
The Netherlands Cancer Institute
University of California, Davis
Fate Therapeutics
Eastern Cooperative Oncology Group
University of Alabama at Birmingham
SWOG Cancer Research Network
Eli Lilly and Company
Intergroupe Francophone de Cancerologie Thoracique
Radiation Therapy Oncology Group
Merck KGaA, Darmstadt, Germany
Swiss Cancer Institute
Eli Lilly and Company